Compare ARBE & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBE | CSBR |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 68.8M |
| IPO Year | 2021 | 2015 |
| Metric | ARBE | CSBR |
|---|---|---|
| Price | $0.55 | $4.84 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 13.7K |
| Earning Date | 11-12-2026 | 09-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | $301.71 | $9.83 |
| Revenue Next Year | $427.31 | $8.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $4.59 |
| 52 Week High | $2.73 | $8.31 |
| Indicator | ARBE | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 31.83 | 43.78 |
| Support Level | N/A | $4.81 |
| Resistance Level | $0.91 | $6.29 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 16.93 | 9.62 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.